NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA converted the C ...

Group 1 - The focus is on income-producing asset classes such as REITs, ETFs, Preferreds, and 'Dividend Champions' that target premium dividend yields up to 10% [1][3] - The iREIT®+HOYA Capital service is designed for income-focused investing, providing opportunities for sustainable portfolio income, diversification, and inflation hedging [2][3] - The investment group aims to help investors achieve dependable monthly income and offers research on various income-focused portfolios [3]

Recent drilling at the Santiago Deposit has successfully extended high-grade gold mineralization by more than 100 metres along strike toward the west, in the direction of the producing Perdido vein, located approximately 600 metres away (See Figure 1). These results, together with ongoing underground drilling at Perdido, support Luca's interpretation that the Santiago and Perdido veins may represent a single, continuous mineralized structure. Current drilling is designed to test the projected strike extensi ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

On CNBC's “Halftime Report Final Trades,” Hightower Advisors’ Stephanie Link said Dick’s Sporting Goods, Inc. (NYSE:DKS) is down 11% from its highs and trades at 11 times earnings. They will fix Foot Locker, Link added. Dick’s completed its purchase of Foot Locker in September.On the earnings front, Dick's Sporting, on Nov. 26, delivered stronger-than-expected results in its core business and lifted full-year guidance. The company reported third-quarter sales of $4.168 billion (+36.3% year over year), which ...

We are in the process of accelerating deglobalization. The process of de-globalization involves decoupling into two blocks: 1) the US-led block with the EU allies and other NATO members, and 2) the China-led block, together with Russia, Iran, and North Korea.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am n ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - BioMarin Pharmaceutical is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion [1] Company Summary - The acquisition will enhance BioMarin's portfolio and expand its capabilities in the biotechnology sector [1] - The deal signifies BioMarin's strategic move to strengthen its position in the market through consolidation [1] Financial Summary - The total value of the acquisition is around $4.8 billion, indicating a significant investment by BioMarin [1]

Core Insights - Jim Wyckoff has over 25 years of experience in stock, financial, and commodity markets, including roles as a financial journalist and market analyst [1][2] - He has covered all futures markets traded in the U.S. and has worked with various news and advisory services [1][2] Company and Industry Summary - Jim Wyckoff operates the "Jim Wyckoff on the Markets" analytical, educational, and trading advisory service [2] - He has held positions as a technical analyst for Dow Jones Newswires and as a senior market analyst with TraderPlanet.com [2] - Wyckoff is also a consultant for the "Pro Farmer" agricultural advisory service and was the head equities analyst at CapitalistEdge.com [2] - He provides daily market updates and technical analysis on Kitco.com [3]

Core Viewpoint - Ørsted A/S (DNNGY) has been assigned a "HOLD" rating due to valuation discrepancies related to volume and other trends [1] Group 1: Company Analysis - The company is under the coverage of a senior analyst with over 10 years of experience in generating value ideas in European and North American markets [1] - The analyst focuses on markets in Scandinavia, Germany, France, the UK, Italy, Spain, Portugal, and Eastern Europe to identify reasonably valued stock ideas [1]